Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare BATS:ARKGNYSEARCA:ARKKNASDAQ:EXAS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARKGARK Genomic Revolution ETF$25.31+7.2%$22.68$17.51▼$31.16$1.38B1.622.76 million shs4.90 million shsARKKARK Innovation ETF$71.09+0.7%$59.89$36.85▼$71.29$6.73B1.649.67 million shs6.26 million shsEXASExact Sciences$52.82-1.9%$53.73$39.97▼$72.83$10.07B0.952.58 million shs1.67 million shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARKGARK Genomic Revolution ETF0.00%+4.13%+13.74%+33.25%+9.28%ARKKARK Innovation ETF0.00%+1.79%+26.14%+69.50%+55.86%EXASExact Sciences0.00%-1.56%-2.88%+24.12%+22.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AN/AN/AN/AEXASExact Sciences4.9418 of 5 stars4.55.00.04.73.42.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARKGARK Genomic Revolution ETF 2.70Moderate Buy$25.31N/AARKKARK Innovation ETF 2.60Moderate Buy$71.09N/AEXASExact Sciences 2.95Moderate Buy$70.4033.30% UpsideCurrent Analyst Ratings BreakdownLatest EXAS, ARKK, and ARKG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $65.005/2/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$55.00 ➝ $75.005/2/2025EXASExact SciencesRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$52.00 ➝ $54.005/2/2025EXASExact SciencesEvercore ISISubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $66.005/2/2025EXASExact SciencesRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$69.00 ➝ $72.004/11/2025EXASExact SciencesGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$60.00 ➝ $60.004/10/2025EXASExact SciencesBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$65.00 ➝ $55.004/10/2025EXASExact SciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$60.004/9/2025EXASExact SciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AN/AN/AN/AEXASExact Sciences$2.83B3.52$5.57 per share9.48$12.98 per share4.07Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARKGARK Genomic Revolution ETFN/AN/A0.00∞N/AN/AN/AN/AN/AARKKARK Innovation ETFN/AN/A50.14∞N/AN/AN/AN/AN/AEXASExact Sciences-$1.03B-$5.51N/A105.6311.39-36.06%-3.75%-1.68%7/30/2025 (Estimated)Latest EXAS, ARKK, and ARKG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/30/2025Q2 2025EXASExact Sciences-$0.04N/AN/AN/A$774.43 millionN/A5/1/2025Q1 2025EXASExact Sciences-$0.37-$0.21+$0.16-$0.54$688.58 million$706.79 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARKGARK Genomic Revolution ETFN/AN/AN/AN/AN/AARKKARK Innovation ETF$0.360.51%N/AN/AN/AEXASExact SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARKGARK Genomic Revolution ETFN/AN/AN/AARKKARK Innovation ETFN/AN/AN/AEXASExact Sciences0.972.732.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARKGARK Genomic Revolution ETFN/AARKKARK Innovation ETFN/AEXASExact Sciences88.82%Insider OwnershipCompanyInsider OwnershipARKGARK Genomic Revolution ETFN/AARKKARK Innovation ETFN/AEXASExact Sciences1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARKGARK Genomic Revolution ETFN/A44.70 millionN/ANot OptionableARKKARK Innovation ETFN/A95.50 millionN/ANot OptionableEXASExact Sciences7,000188.64 million186.37 millionOptionableEXAS, ARKK, and ARKG HeadlinesRecent News About These CompaniesVontobel Holding Ltd. Grows Stock Holdings in Exact Sciences Corporation (NASDAQ:EXAS)July 5 at 4:37 AM | marketbeat.comAnalysts Set Exact Sciences Corporation (NASDAQ:EXAS) Target Price at $70.40July 5 at 2:49 AM | americanbankingnews.comKBC Group NV Sells 200,000 Shares of Exact Sciences Corporation (NASDAQ:EXAS)July 4 at 4:13 AM | marketbeat.comExact Sciences Corporation (NASDAQ:EXAS) Stock Position Cut by Sumitomo Mitsui Trust Group Inc.July 3 at 4:32 AM | marketbeat.comWilliam Blair Predicts Increased Earnings for Exact SciencesJuly 3 at 2:19 AM | americanbankingnews.comQ2 EPS Estimates for Exact Sciences Lifted by William BlairJuly 2, 2025 | marketbeat.comExact Sciences Corporation (NASDAQ:EXAS) Given Average Recommendation of "Moderate Buy" by BrokeragesJuly 2, 2025 | marketbeat.comConcerns Rise Over Exact Sciences Corp. (EXAS) Salesforce Reorganization Affecting GrowthJune 30, 2025 | msn.comPeregrine Capital Management LLC Cuts Position in Exact Sciences Corporation (NASDAQ:EXAS)June 30, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Buys 111,343 Shares of Exact Sciences Corporation (NASDAQ:EXAS)June 30, 2025 | marketbeat.comCraig-Hallum Sticks to Its Buy Rating for Exact Sciences (EXAS)June 29, 2025 | theglobeandmail.comExact Sciences Corporation (NASDAQ:EXAS) Shares Acquired by Skylands Capital LLCJune 29, 2025 | marketbeat.comEXAS - Exact Sciences Corp Price vs Fair Value | MorningstarJune 28, 2025 | morningstar.comMArtemis Investment Management LLP Purchases 12,758 Shares of Exact Sciences Corporation (NASDAQ:EXAS)June 28, 2025 | marketbeat.comExact Sciences (NASDAQ:EXAS) Shares Up 4.5% - Here's What HappenedJune 27, 2025 | marketbeat.comEXAS - Exact Sciences Corp Financials - MorningstarJune 26, 2025 | morningstar.comMThe 5 Most Interesting Analyst Questions From Exact Sciences’s Q1 Earnings CallJune 26, 2025 | msn.comExact Sciences Corporation (NASDAQ:EXAS) Stock Position Lifted by Beech Hill Advisors Inc.June 26, 2025 | marketbeat.comGoldstein Advisors LLC Boosts Stake in Exact Sciences Corporation (NASDAQ:EXAS)June 26, 2025 | marketbeat.comGlobal Assets Advisory LLC Takes Position in Exact Sciences Corporation (NASDAQ:EXAS)June 26, 2025 | marketbeat.comBarclays Has Lowered Expectations for Exact Sciences (NASDAQ:EXAS) Stock PriceJune 26, 2025 | americanbankingnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseUber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesBy Leo Miller | June 25, 2025View Uber and Tesla Surge on Robotaxis, Analyst Touts Texas RidesTexas Instruments Stock: Congress Likes It, Should You Too?By Thomas Hughes | June 24, 2025View Texas Instruments Stock: Congress Likes It, Should You Too?EXAS, ARKK, and ARKG Company DescriptionsARK Genomic Revolution ETF BATS:ARKG$25.31 +1.70 (+7.20%) Closing price 07/3/2025 03:50 PM EasternExtended Trading$25.40 +0.10 (+0.38%) As of 07/3/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.ARK Innovation ETF NYSEARCA:ARKK$71.09 +0.51 (+0.72%) As of 07/3/2025 05:00 PM EasternThe ARK Innovation ETF (ARKK) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that seeks long-term capital growth from companies globally involved with, or that benefit from, disruptive innovation. ARKK was launched on Oct 31, 2014 and is managed by ARK.Exact Sciences NASDAQ:EXAS$52.82 -1.05 (-1.94%) Closing price 07/3/2025 03:12 PM EasternExtended Trading$52.82 0.00 (0.00%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
